ActiTrexx

Quell Therapeutics

This clinical-stage company develops engineered T-regulatory cell therapies for patients with autoimmune diseases, inflammatory conditions and organ transplant rejection.

Regcell

This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.

Tr1X

This biotechnology company develops allogeneic engineered regulatory T cell therapies to treat patients with autoimmune and inflammatory diseases.

Sonoma Biotherapeutics

This biotechnology company develops engineered regulatory T cell therapies for patients with autoimmune and inflammatory diseases.

Thymmune

This biotechnology company develops scalable thymic cell therapies to restore immune function for patients with immunodeficiencies, autoimmune disorders, and transplant-related conditions.

Candid Therapeutics

This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.

Egle Therapeutics

This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.

TRexBio

This biotechnology company develops immunoregulatory medicines for patients with autoimmune and inflammatory diseases by decoding regulatory T cell function in human tissues.